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Summary: We studied the plasma and urinary excretion levels of aluminum (Al) on day 0, 10 and 30 in 79 patients
with gastrointestinal symptoms and normal renal function who were receiving a complex based on Al allantoinates
[C4H5N4 O3 Al (OH)2] and [C4H5N4 O3 Cl A12 (OH)4]. We evaluated the extent of Al absorption after repeated
administration of this complex in two antacid formulations, Ulfon Lyoc® in lyophilised tablet form (group 1;
n = 40) and Ulfon® suspension (group 2; n = 39). The total Al load for each antacid and patient was 512 mg daily
for a total of 15360 mg during the 30-day treatment. No significant rise in plasma Al concentration was noted with
either formulation between day 0 and 10, day 0 and 30 or day 10 and 30, nor was there any significant increase in
urinary excretion levels. Al absorption was not increased and no toxic effects were noted, indicating that such
formulations are suitable for long-term therapy in patients with gastrointestinal symptoms.
Introduction
Aluminium (Al), a ubiquitous contaminant, is routinely
used in antacid form to prevent or treat gastric lesions,
gastro-oesophageal reflux or oesophagitis in patients
with normal renal function (1, 2). Studies have shown
an increase in serum Al levels in healthy subjects or in
patients with chronic renal failure after oral ingestion of
various compounds usually containing Al hydroxide (3)
or sucralfate (4), respectively, as phosphate binders.
Aluminium toxicity syndrome was described in 1976 by
Alfrey et al. (5) in the context of dialysis encephalopathy,
but it can also occur in patients with impaired excretory
renal function not yet requiring haemodialysis (6, 7);
these effects indicate that the gastrointestinal tract plays
an important role in Al absorption from phosphate-bind-
ing drugs. Moreover, high concentrations of the metal
have been found in brain tissues of healthy subjects
treated with Al hydroxide (8).
This study was conducted over a 30-day period in
patients with gastrointestinal symptoms and normal
renal function to determine the levels of intestinal Al
absorption from the allantoinate-based complexes
[C4H5N403A1 (OH)2] and C4H5N4O3C1 A12 (OH)4] con-
tained in two different antacid formulations: Ulfon Ly-
oc® lyophilised tablets and Ulfon®suspension, both
manufactured by L. Lafon Laboratories (F-94701 Mai-
sons-Alfort Cedex France). The study was performed be-
cause the effects of repeated Al ingestion are largely un-
known in such patients, and long-term therapy therefore
represents a potential risk.
Patients and Methods
Subjects
After approval by the Local Ethics Committee, the study protocol
was carried out at the Jean Bernard Hospital, Poitiers, France. Ex-
periments were performed in 79 patients (two groups) with gastro-
intestinal symptoms, each of whom gave informed written consent.
The first group consisted of 40 patients (20 men, 20 women; mean
age ± standard deviation 44.05 ± 11.94 years, range 20—75)
weighing between 50 and 95 kg (mean ± standard deviation 68.5
± 13.1). The second group (19 men, 20 women; mean ± standard
diviation 52.47 ± years, range 23—75) weighed between 47 and
90 kg (mean ± standard deviation 67.6 ± 12.59).
The 79 patients were included in the study on the basis of in-
terviews concerning their past medical history and the existence of
painful symptoms warranting 30-day prescription of an antacid.
The patients excluded had renal disease (serum creatinine measure-
ment), ulcer complications (bleeding, perforation), recorded hepati-
tis or cardiovascular problems. During the selection process,
plasma was screened for Australia antigen and HTLV III antibod-
ies. The following medications were prohibited during the treat-
ment: acetylsalicylic acid, anti-inflammatory agents, other antacids
(e. g. cimetidine, ranitidine) and Al salts. Patients were told to eat
three regular meals per day and to avoid foods producing ulcer
symptoms. Alcoholic beverages were not allowed.
Drug composition and treatment
The antacids contained a complex based on Al allantoinates, a
chemical combination of Al dihydroxy (900 mg) and chlorhydroxy
(100 mg) allantoinates with calcium carbonate (500 mg). This
water-insoluble complex (9) was presented in two different formu-
lations, each containing 128 mg of Al. Patients in group 1 orally
ingested Ulfon Lyoc®, a lyophilised tablet which melts under the
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tongue without water, and group 2 received Ulfon® suspension in
small bags. A tablet or bag was administered one hour after break-
fast, lunch and dinner and before bedtime (four doses per day for
30 days) which corresponds to 512 mg of Al per day, the therapeu-
tic dose currently used in antacids for gastrointestinal symptoms.
Procedures and study design
The main assessment criteria were plasma and urinary AJ concen-
trations determined on day 0 (baseline and onset of treatment), 10
and 30 (end of treatment). All blood samples were obtained from
fasting patients before antacid intake. Complementary blood tests
were performed on day 0 and 30 for creatinine, glucose, calcium,
magnesium, phosphorus, sodium, potassium, iron. All patients un-
derwent in-depth medical tests on day 0 and 30. Patients would
have been excluded from the study if they had presented a serious
illness, required surgery or had side effects associated with the
treatment.
Blood and urine sampl ing and assay
As Al is a ubiquitous element, great care was taken at all stages of
preparation to avoid any risk of sample contamination. The pro-
cedure used has already been described by Guillard et al. (10). No
glassware was used. Polystyrene tubes and polyethylene bottles
(PolyLabo and Paul Block, Strasbourg, France), used respectively
for blood and urine collection, were washed in acid HC1 (6.30
mol/1) (Merck, Suprapur, Darmstadt, Germany), rinsed with "ultra-
pure" water and checked for Al contamination (Al level less than
0.037 μηιοΐ/ΐ). Blood samples were obtained from each patient
(two tubes for each patient) using a 0.7 mm Vygon® "epicranium"
needle (Ecouen, France) designed to allow blood to enter drop by
drop into 3-ml heparinized polystyrene tubes (ΑΙ-free heparin). Af-
ter centrirugation, plasma was immediately stored at — 20 °C. For
24-h urine, successive micturitions were collected to limit contami-
nation, as recommended by Griffin (11), and samples were stored
at — 20 °C until analysed. Al measurements were performed on a
Perkin-Elmer Zeeman 5000 equipped with a HGA 500 graphite
atomizer and an AS 40 autosampler (all from Perkin-Elmer Corp.,
Norwalk. CT, USA). The technique described for element assay in
blood has been applied to urine assay with a detection limit of
0.03 μηκοΐ/ΐ.
Qual i ty assurance
Each Al calibration was monitored with two quality controls, one
for plasma (Seronorm®, Nycomed, Oslo, Norway) and the other
for urine (Bio-Rad®, Anaheim, CA, USA). In addition, analytical
performance was monitored by participation in two interlaboratory
surveys: the Guildford trace element external quality assessment
scheme (12) (Guildford, Surrey, UK) and the "Centre de Toxicolo-
gie du Quebec" Interlaboratory comparison program (13). The ac-
curacy for these two quality assessment schemes is about 10%.
Statistics
Data management and statistical calculation were carried out using
the 4.02 version of Statgraphics software (S. T. S. C, Anaheim, CA,
USA). Results are reported as mean ± SD. Data were analysed
using Student's /-test for paired samples to assess significant differ-
ences for each group between day 0 (baseline) and 10, 0 and 30
and 10 and 30. P < 0.001 was considered statistically significant.
Results
In table 1, there were no significant increases over base-
line plasma Al levels (day 0) in patients of either group
on day 10 or 30, and the range of Al levels during both
treatments (0.12 to 0.90 μιηοΐ/ΐ) remained close to base-
line values (0.17 to 0.44 μιηοΐ/ΐ). Similar results were
found for urinary Al excretion (tab. 2), with values on
day 10 (0.04-0.32 μπκ>1/24Γΐ) and 30 (0.05-0.33
μΐϊΐοΙ/24 h) showing no significant differences from the
baseline (day 0) values (0.05-0.29 μιηοΙ/24 h).
No significant differences in biochemical quantities
were noted for any patient in either group between day
0 and 30.
Discussion ,
Aluminium, a ubiquitous contaminant, is neurotoxic in
patients with chronic renal failure (5). The renal system
is primarily responsible for aluminium excretion (16).
High oral doses of ΑΙ-containing phosphate binders are
prescribed for these patients (5, 17), and Al hydroxide,
the compound most widely used in the formulation for
phosphate regulation, may increase Al uptake (18), lead-
ing to neurodegenerative disorders (5) and other toxic
symptoms including microcytic and vitamin D-resistant
osteomalacia. Sucralfate, the phosphate binder of choice
in patients with uraemia and peptic ulceration (4), often
Tab. 1 Plasma aluminium concentration in patients determined
on day 0, 10 and 30.
























Group 1: η = 40; Group 2: η = 39 with mean ± SD and range.
a: Not significantly different between day 0 (baseline) and day 10.
b: Not significantly different between day 0 (baseline) and day 30.
Tab. 2 Urinary aluminium excretion in patients determined on
day 0, 10 and 30.





















Group 1: n = 40; Group 2: n = 39 with mean ± SD and range.
a: Not significantly different between day 0 (baseline) and day 10.
b: Not significantly different between day 0 (baseline) and day 30.
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causes increased plasma Al and has been associated with
toxicity (19). Aluminium in antacid form has also been
widely prescribed in adults to prevent or treat gastric
lesions and reduce the incidence of stress ulceration (1,
2). In all these treatments, Al absorption depends on the
chemical species of Al salts ingested. Aluminium hy-
droxide (2) and sucralfate (20) are most widely em-
ployed as oral Al medication in antacids for prophylactic
or therapeutic use, but few studies other than those of
Schütze et al. (21) have dealt with Al accumulation in
patients with normal renal function, particularly when
pathological factors modify absorption, as with gastroin-
testinal symptoms in our study. In fact, De Wolff & Van
der Voet (22) have suggested that intestinal absorption
is the main route of Al entry into the body.
The risk of hyperaluminaemia occurring would appear
to be high in our study after long-term therapy with the
allantoinate complex containing 128 mg of Al per for-
mulation (Ulfon Lyoc® or Ulfon® suspension). The four
daily samples produced a total of 15360 mg of alumin-
ium ingested by each patient during the 30-day treat-
ment period. In our study, the values recorded in both
groups (tables 1 and 2) show that after the 30-day treat-
ment period, there is no increase in plasma and urinary
Al, a finding which appears to indicate no Al accumula-
tion or toxicity conducive to the neuronal disorders at-
tributed to this metal.
These results contrast with findings for other compounds
such as Al hydroxide (3), sucralfate in healthy subjects
(23, 24), or in patients with peptic ulcer disease with
normal renal function (21). Kaehny et al. (3) clearly de-
monstrated high plasma Al levels in normal adults who
ingested Al hydroxide, as compared with those receiving
Al phosphate and controls. More strikingly, Kisters et al.
(8) found significantly increased Al concentrations in
the brain tissues of healthy patients with normal kidney
function who ingested 2 g of Al hydroxide daily for 14
days (total Al load 9682 mg), as compared with controls.
This report showed that Al entered the brain by passing
through the blood-brain barrier. In the light of this study
by Kisters et al. (8), Deloncle et al. (25) demonstrated
the increased ability of Al to enter erythrocytes in vitro
as well as rat brain in the presence of L-glutamate
through the formation of a complex capable of crossing
membranes.
In healthy subjects receiving sucralfate therapy, very
high urinary excretion has been reported after 3 days of
administration (26) as well as high plasma concentra-
tions after 21 days (23) or even after 72 hours, in a
study using both tablet and suspension formulations (24)
corresponding to a total Al of 828 mg, 17640 mg and
210 mg respectively. In contrast, Nagy & Jobs t (27) ob-
served an increase in urinary Al but not in plasma Al in
healthy subjects receiving 18 tablets, each containing 58
mg of Al in the form Al2Mg4(OH)12CO3 administered
during 37 h (total Al load 1044 mg). Weberg & Berstad
(28) concluded the measurement of urinary excretion is
a more sensitive method than determination of the
plasma level for detecting Al absorption, which may ex-
plain why Kinoshita et al. (29) found no significant
increase in plasma concentrations after sucralfate admin-
istration in ulcer patients. However, the present study
involving patients with gastrointestinal symptoms and
normal kidneys showed no significant increase in urin-
ary Al during the 30-day treatment period, and presuma-
bly no increased intestinal absorption since it has been
demonstrated that urinary Al excretion reflects enhanced
ingestion (16).
The positive effects of this Al allantoinate complex in
treating gastro-duodenal affections have been demon-
strated in man (30), and another study has shown that
the healing action is due to allantoin (31). All these ex-
periments were carried out with the "powdered" formu-
lation, and no study on Al absorption was reported. The
pharmaceutical preparation is of considerable interest
since the activity of an antacid depends on its miscibility
within gastric contents. The suspension form is one of
the best pharmaceutical preparations since it allows
good contact of the antacid with the stomach's acid
phase; the Ulfon Lyoc® form possesses these same prop-
erties when kept in contact with buccal mucosa and al-
lowed to dissolve under the tongue.
Our measurements of Al concentrations in plasma and
urine are close to the reference values for healthy sub-
jects reported by Versieck & Cornells (14) and Pineau
et al. (15). These determinations require high analytical
accuracy, precision and reproducibility. Given the ubi-
quity of this metal and the greater risk of contamination,
rigorous, meticulously applied steps were followed from
the time of plasma collection, as described by Guillard
et al. (10). In addition, analytical performance was mon-
itored by participation in two quality control schemes
(12, 13) and in conformity with the Worldwide Interlab-
oratory Aluminium Quality Control program (32). As
Hewitt et al. (33) point out, interlaboratory schemes have
brought considerable improvement in analytical methods
for Al analysis by enabling laboratories to identify
sources of contamination and analytical problems.
We may conclude that administration of 512 mg Al per
day during 30-day antacid therapy with Ulfon Lyoc®
and Ulfon® suspension formulations did not enhance Al
plasma concentration or urinary excretion in patients
treated for gastrointestinal symptoms.
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